

AMENDMENT TRANSMITTAL LETTER

APR-09-1999

ATTORNEY DOCKET NO.

16715/CIP

Serial No.
08/902,692Filing Date
7/30/97Examiner
Schwadron, R.Group Art Unit
1644

INVENTION

AUTOGENOUS LYMPHATIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional fee is required.
- The fee has been calculated as shown below:

	(1) CLAIMS REMAINING AFTER AMENDMENT	(2) HIGHEST NO PREVIOUSLY PAID FOR	(3) PRESENT EXTRA
TOTAL	34	48	0
INDEP	3	4	0
FIRST PRESENTATION OF MULTIPLE DEP CLAIM			

SMALL ENTITY		OTHER THAN A SMALL ENTITY	
RATE	ADDITIONAL FEE	RATE	ADDITIONAL FEE
x \$ 9 =	0	x \$18 =	0
x \$39 =	0	x \$78 =	0
\$130	0	\$260	0
TOTAL ADDITIONAL FEE		TOTAL	
0		0	

If the entry in Col 1 is less than the entry in Col 2 write "0" in Col 3
 If the Highest No Previously Paid For IN THIS SPACE is less than 20 enter "20"
 If the Highest No Previously Paid For IN THIS SPACE IS LESS THAN 3 ENTER "3"
 The Highest No Previously Paid For (Total or Indep) is the highest number found in the appropriate box in Col 1

- Please charge my Deposit Account No. 03-3840 in the amount of \$_____ A duplicate copy of this sheet is enclosed.
- A check in the amount of \$_____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3840. A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 CFR 1.16.
- Any patent application processing fees under 37 CFR 1.17

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed for the HON. COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, D. C. 20231 on:

Respectfully submitted,

MAILING CENTER
SERVICE CENTERTodd E. Albane

Todd E. Albane, Reg. 36,426

CRUTSINGER & BOOTH

1601 Elm Street, Suite 1950

Dallas, Texas 75201-4744

(214) 220-0444; Fax (214) 220-0445

April 7, 1999

Date of Deposit

Todd E. Albane

Name of Applicant, Assignee or Registered Representative

Todd E. Albane

Signature

April 7, 1999

Date of Signature

Attorneys for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William J. Rea, MD, et al

Attorney Docket: 16715/CIP

Serial No.: 08/902,692

Art Group Unit: 1644

Filed: July 30, 1997

Examiner: Schwadron, R.

For: **AUTOGENOUS LYMPHATIC FACTOR FOR
MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**

12/B
M.J.J
4/16/99

AMENDMENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 12, 1999 and a short telephone interview on March 16, 1999, please amend the application as follows:

In the Title:

~~Please change the title to – Method Of Treating A Chemically Sensitive Individual –~~

In the Specification:

- ~~At page 1, line 13, please delete “normal”.~~
- ~~At page 3, line 7, delete “normal”.~~
- ~~At page 3, line 15, delete “normal”.~~
- ~~At page 6, lines 9-10, delete “normal (non-cancerous or otherwise dysfunctional)”.~~
- ~~At page 6, line 16, delete “normal”.~~
- ~~At page 8, line 22, delete “normal”.~~

In the Abstract of the Disclosure:

Please delete the entire text of the abstract in favor of the following new text:

B
– A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating ^{normal} mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be